DPYSL2 (Ab-509) Antibody

What is DPYSL2 (Ab-509) Antibody and what epitope does it recognize?

DPYSL2 (Ab-509) Antibody is a polyclonal antibody raised in rabbits that specifically recognizes the Collapsin Response Mediator Protein 2 (CRMP2) around the phosphorylation site of threonine 509 (S-V-T(p)-P-K). This antibody detects endogenous levels of total CRMP2 protein and is designed for research applications only. The antibody is generated using a synthesized non-phosphopeptide derived from human CRMP-2 and is affinity-purified from rabbit antiserum using epitope-specific immunogen .

What applications is DPYSL2 (Ab-509) Antibody validated for?

DPYSL2 (Ab-509) Antibody has been validated for multiple research applications including:

• Western Blotting (WB): Recommended dilution range of 1:500-1:3000

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Immunohistochemistry (IHC): Recommended dilution range of 1:50-1:100

These applications have been validated using various cellular and tissue samples, including human brain tissue and cell lines such as HT-29 and COS7 .

What are the optimal storage conditions for maintaining antibody efficacy?

For long-term storage, DPYSL2 (Ab-509) Antibody should be stored at -20°C or -80°C upon receipt. For frequently used antibodies, short-term storage at 4°C for up to one month is acceptable. It is crucial to avoid repeated freeze-thaw cycles as this can compromise antibody functionality. The antibody is typically supplied in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150mM NaCl, 0.02% sodium azide, and 50% glycerol to maintain stability .

What species reactivity has been confirmed for this antibody?

The DPYSL2 (Ab-509) Antibody has been confirmed to react with CRMP2 protein from human and mouse samples. Cross-reactivity with rat samples has been reported for similar DPYSL2 antibodies targeting nearby phosphorylation sites, suggesting potential utility across these three mammalian model systems .

How should I design positive and negative controls when using DPYSL2 (Ab-509) Antibody?

For rigorous experimental design with DPYSL2 (Ab-509) Antibody:

Positive Controls:

• Human brain tissue samples known to express CRMP2

• Cell lines with confirmed CRMP2 expression (HT-29, COS7)

• Heat-shocked cells that may alter phosphorylation status of CRMP2

Negative Controls:

• Antibody pre-absorption with synthesized peptide: As demonstrated in the Western blot analysis of extracts from COS7 cells, pre-treatment of the antibody with synthesized peptide eliminates signal, confirming specificity

• DPYSL2/CRMP2 knockout samples: CRISPR/Cas9-edited cells with DPYSL2 knockout can serve as excellent negative controls

• Secondary antibody-only controls to assess non-specific binding

This approach ensures signal specificity and minimizes false positives in your experimental system.

What are the recommended sample preparation methods to preserve phosphorylation status?

To accurately assess CRMP2 phosphorylation status at Thr509, implement these critical sample preparation steps:

• Use ice-cold lysis buffers containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate)

• Maintain samples at 4°C throughout processing

• Add protease inhibitors to prevent protein degradation

• Process samples quickly to minimize dephosphorylation

• Consider including 1-5 mM EDTA to inhibit metalloproteases

• For tissue samples, snap-freeze immediately after collection

• When comparing phosphorylation levels, normalize phospho-CRMP2 to total CRMP2 protein as demonstrated in Huntington's disease research protocols

These measures are particularly important when analyzing disease models where altered phosphorylation may be subtle but biologically significant.

How can I quantify and normalize Western blot results for phospho-CRMP2 detection?

For accurate quantification of phospho-CRMP2 levels:

• Run technical replicates (at least three separate immunoblotting experiments)

• Normalize phospho-CRMP2 signal by total CRMP2 from individual samples

• Use GAPDH as a loading control for total protein normalization

• Employ densitometry software to quantify band intensity

• Pool normalized data from separate experiments for statistical analysis

• Present results as mean ± standard deviation

• Apply appropriate statistical tests for comparing control versus experimental groups

This methodology has been successfully employed in studies examining CRMP2 phosphorylation status in neurodegenerative disorders such as Huntington's disease, where researchers detected significant hyperphosphorylation at Thr509/514 sites in HD patient brain samples compared to controls .

What is the functional significance of CRMP2 phosphorylation at Threonine 509?

CRMP2 phosphorylation at Threonine 509 represents a critical regulatory mechanism for its function in neuronal development and cellular processes:

• Cytoskeletal Regulation: Phosphorylation at Thr509 reduces CRMP2's binding affinity for tubulin, affecting microtubule assembly and stabilization

• Neuronal Morphology: This modification influences neurite outgrowth and axonal extension, as evidenced by studies showing reduced dendrite length in neurons with altered CRMP2 phosphorylation

• Cellular Signaling: Thr509 phosphorylation is part of a regulatory cascade that involves mTOR signaling pathways, connecting cellular metabolism to cytoskeletal dynamics

• Mitochondrial Function: Research suggests that CRMP2 may regulate mitochondrial dynamics in a phosphorylation-dependent manner, potentially modulating neuronal survival in neurodegenerative conditions like Huntington's disease

This phosphorylation site represents an important target for understanding neurological disease mechanisms and potential therapeutic interventions.

How does CRMP2 phosphorylation status differ between normal and disease states?

Research has revealed significant differences in CRMP2 phosphorylation between healthy and pathological conditions:

These differential phosphorylation patterns can be detected using phospho-specific antibodies like DPYSL2 (Ab-509) and may serve as potential biomarkers or therapeutic targets in neurological disorders .

What is the relationship between CRMP2 isoforms and their phosphorylation patterns?

CRMP2 exists in multiple isoforms with distinct functions and phosphorylation patterns:

• CRMP2-A vs CRMP2-B: These major isoforms differ in their N-terminal regions, affecting their localization and function. CRMP2-B is the predominant isoform in neurons and appears particularly relevant for neuropsychiatric disorders.

• Isoform-specific regulation: Research using CRISPR/Cas9 to specifically knock out DPYSL2-B isoform demonstrated:

  • 3-fold reduction in DPYSL2-B expression

  • Drastic reduction in CRMP2-B protein

  • Up to 58% reduction in dendrite length in neurons

  • Transcriptome disruptions in pathways relevant to psychiatric disease

• Phosphorylation site accessibility: Different isoforms may present varied accessibility to kinases that phosphorylate sites like Thr509 and Ser522, resulting in isoform-specific phosphorylation patterns.

When using DPYSL2 (Ab-509) Antibody, researchers should consider which isoforms are expressed in their experimental system and how this might influence interpretation of phosphorylation data .

How can I use DPYSL2 (Ab-509) Antibody to study neuropsychiatric disorders?

To effectively utilize DPYSL2 (Ab-509) Antibody in neuropsychiatric disorder research:

• iPSC-derived neuronal models: Generate patient-specific or CRISPR-edited iPSCs and differentiate them into neurons to study CRMP2 phosphorylation in disease-relevant contexts. This approach has been successfully used to study DPYSL2-B isoform's role in schizophrenia .

• Transcriptomic correlation: Combine phosphorylation analysis using DPYSL2 (Ab-509) Antibody with RNA-seq to identify relationships between CRMP2 phosphorylation and gene expression changes. Research has shown disruptions in pathways highly relevant to psychiatric disease including mTOR signaling, cytoskeletal dynamics, and calcium signaling in DPYSL2-B knockout models .

• Integration with GWAS data: Correlate CRMP2 phosphorylation patterns with known GWAS loci for conditions like schizophrenia. Studies have demonstrated significant enrichment of differentially expressed genes in CRMP2-altered cells within schizophrenia GWAS-associated loci .

• Drug response studies: Use the antibody to monitor changes in CRMP2 phosphorylation in response to psychiatric medications, potentially identifying novel therapeutic mechanisms.

This multifaceted approach can provide deeper insights into how CRMP2 phosphorylation contributes to neuropsychiatric pathophysiology.

What experimental approaches can detect changes in CRMP2 phosphorylation dynamics?

To effectively capture dynamic changes in CRMP2 phosphorylation:

• Time-course experiments: Monitor phosphorylation changes at different time points following stimulation or treatment using DPYSL2 (Ab-509) Antibody in Western blot analysis.

• Phosphorylation site multiplexing: Combine antibodies targeting different phosphorylation sites (Thr509, Ser522) to create a comprehensive phosphorylation profile of CRMP2 in your samples .

• Live-cell imaging: Couple phospho-specific antibodies with proximity ligation assays or phospho-sensors to visualize CRMP2 phosphorylation dynamics in living cells.

• Mass spectrometry validation: Complement antibody-based detection with mass spectrometry to identify and quantify multiple phosphorylation sites simultaneously.

• Kinase and phosphatase inhibitor treatments: Apply specific inhibitors to identify the enzymes responsible for regulating CRMP2 phosphorylation at Thr509.

These approaches provide complementary information about the temporal and spatial regulation of CRMP2 phosphorylation in normal and pathological conditions.

How can I investigate the relationship between CRMP2 phosphorylation and mitochondrial dynamics?

To explore the emerging connection between CRMP2 phosphorylation and mitochondrial function:

• Co-localization studies: Use DPYSL2 (Ab-509) Antibody in combination with mitochondrial markers to assess whether phosphorylated CRMP2 localizes to mitochondria under different conditions.

• Mitochondrial morphology analysis: Examine changes in mitochondrial shape, size, and network organization in models with altered CRMP2 phosphorylation status.

• Functional assays: Measure mitochondrial membrane potential, respiration rates, and ATP production in relation to CRMP2 phosphorylation levels.

• Interaction partners: Identify mitochondrial proteins that interact with phosphorylated or non-phosphorylated CRMP2 using co-immunoprecipitation followed by mass spectrometry.

• Genetic manipulation: Create phospho-mimetic or phospho-deficient CRMP2 mutants at Thr509 and assess effects on mitochondrial dynamics.

Research has already suggested that CRMP2 may regulate mitochondrial dynamics in a phosphorylation-dependent manner and modulate neuronal survival in Huntington's disease, opening exciting new avenues for investigation .

What steps should I take if I observe weak or no signal when using DPYSL2 (Ab-509) Antibody?

If you encounter weak or absent signal when using DPYSL2 (Ab-509) Antibody, implement this systematic troubleshooting approach:

• Antibody concentration optimization:

  • Titrate the antibody using a wider range than recommended (1:250-1:5000)

  • Create a dot blot with purified protein to determine minimal detection threshold

• Sample preparation improvements:

  • Ensure complete protein extraction with appropriate lysis buffers

  • Verify protein integrity with Ponceau S or total protein stains

  • Confirm target protein expression in your sample type

• Phosphorylation preservation:

  • Add fresh phosphatase inhibitors to all buffers

  • Maintain samples at 4°C throughout processing

  • Consider using phosphatase stimulation (treatment with okadaic acid) as a positive control

• Detection system enhancement:

  • Use high-sensitivity ECL substrates for Western blotting

  • Consider signal amplification systems for IHC applications

  • Optimize secondary antibody concentration independently

• Technical modifications:

  • For Western blots, try longer transfer times for higher molecular weight proteins

  • For IHC, test different antigen retrieval methods (heat-induced vs. enzymatic)

  • Consider membrane type (PVDF vs. nitrocellulose) for Western blotting

This methodical approach addresses the most common causes of weak or absent signals in antibody-based applications.

How should I interpret conflicting results between phospho-specific and total CRMP2 antibodies?

When faced with discrepancies between phospho-specific (like DPYSL2 Ab-509) and total CRMP2 antibody results:

• Evaluate epitope masking possibilities:

  • Determine if protein-protein interactions might block antibody access

  • Consider whether other post-translational modifications near Thr509 affect antibody binding

  • Test different denaturing conditions that might expose hidden epitopes

• Assess phosphorylation dynamics:

  • Remember that phosphorylation is transient and highly regulated

  • Compare sample handling procedures that might affect phosphorylation status

  • Consider that only a fraction of total protein may be phosphorylated at any time

• Check isoform specificity:

  • Determine which CRMP2 isoforms your antibodies recognize

  • CRMP2-A (~72kD) and CRMP2-B may show different patterns

  • Verify if your experimental system expresses all relevant isoforms

• Conduct validation experiments:

  • Use phosphatase treatment to confirm phospho-specificity

  • Include CRMP2 knockout samples as negative controls

  • Consider using recombinant phosphorylated and non-phosphorylated proteins as standards

This analytical approach helps resolve apparently contradictory results and may reveal unexpected biological insights.

How can DPYSL2 (Ab-509) Antibody contribute to research on mTOR signaling in neuropsychiatric disorders?

DPYSL2 (Ab-509) Antibody offers valuable insights into the intersection of mTOR signaling and CRMP2 function in neuropsychiatric research:

• Mechanistic connections: Recent studies have established that a schizophrenia-associated polymorphic CT dinucleotide repeat in the DPYSL2-B isoform responds to mammalian target of Rapamycin (mTOR) signaling. DPYSL2 (Ab-509) Antibody can be used to monitor how mTOR pathway modulation affects CRMP2 phosphorylation at Thr509 .

• Drug discovery applications: Researchers can employ the antibody to screen compounds that target mTOR signaling and assess their effects on CRMP2 phosphorylation, potentially identifying novel therapeutic approaches for conditions like schizophrenia.

• Integrative experimental designs: Combining DPYSL2 (Ab-509) Antibody with transcriptomic analysis has revealed that CRMP2 alterations create expression signatures that contrast with those induced by antipsychotic drugs, providing a platform for drug mechanism studies .

• Translational research potential: The antibody can help bridge basic research findings to clinical applications by assessing whether patient-derived samples show altered CRMP2 phosphorylation patterns that correlate with disease severity or treatment response.

This research direction represents a promising frontier in understanding the molecular basis of neuropsychiatric disorders and developing more targeted therapeutic interventions.

What role does CRMP2 phosphorylation play in neurodegenerative diseases beyond Huntington's disease?

CRMP2 phosphorylation has emerging significance across multiple neurodegenerative conditions:

• Alzheimer's Disease (AD):

  • Hyperphosphorylated CRMP2 has been found in neurofibrillary tangles

  • Phosphorylation at sites including Thr509 may contribute to axonal transport deficits

  • DPYSL2 (Ab-509) Antibody could help track disease progression at the molecular level

• Parkinson's Disease (PD):

  • Altered CRMP2 phosphorylation may affect dopaminergic neuron vulnerability

  • Recent studies suggest connections between CRMP2 and α-synuclein pathology

  • Phosphorylation status could influence mitochondrial dynamics, particularly relevant in PD

• Amyotrophic Lateral Sclerosis (ALS):

  • CRMP2 phosphorylation changes may contribute to motor neuron degeneration

  • The role of CRMP2 in axonal transport becomes critical in the long axons affected in ALS

  • Research using DPYSL2 (Ab-509) Antibody could reveal disease-specific modifications

• Multiple Sclerosis (MS):

  • CRMP2's role in myelination and oligodendrocyte function suggests relevance to MS

  • Phosphorylation at Thr509 might influence remyelination capacity

  • Inflammatory signals may trigger specific CRMP2 phosphorylation patterns

This expanding research area highlights the need for reliable phospho-specific antibodies like DPYSL2 (Ab-509) to characterize disease-specific modifications and identify potential therapeutic targets .

How might single-cell techniques incorporate DPYSL2 (Ab-509) Antibody for neurodevelopmental research?

Integrating DPYSL2 (Ab-509) Antibody into emerging single-cell techniques offers powerful new approaches for neurodevelopmental research:

• Single-cell phospho-proteomics:

  • Adapt antibody-based detection for mass cytometry (CyTOF) to quantify CRMP2 phosphorylation at Thr509 in individual cells

  • Correlate phosphorylation status with cell type, developmental stage, and disease state

  • Identify rare cell populations with distinct CRMP2 phosphorylation patterns

• Spatial transcriptomics integration:

  • Combine DPYSL2 (Ab-509) Antibody immunostaining with spatial transcriptomics to correlate phosphorylation patterns with gene expression in intact tissue

  • Map CRMP2 phosphorylation dynamics across brain regions during development

  • Identify microenvironmental factors influencing CRMP2 regulation

• Live-cell imaging in developmental contexts:

  • Develop antibody-based biosensors to track CRMP2 phosphorylation in differentiating neurons

  • Monitor real-time changes during neuronal polarization and axon specification

  • Assess how extracellular cues trigger CRMP2 phosphorylation cascades

• iPSC-derived brain organoids:

  • Apply DPYSL2 (Ab-509) Antibody to track CRMP2 phosphorylation during organoid development

  • Compare patterns between control and disease-specific organoids

  • Test how genetic modifications of DPYSL2, particularly in the B isoform, affect neuronal organization and connectivity